Skip to main content
SpringerLink
Log in

Comparative Pharmacology of Newer Progestogens

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Summary

The newer progestogens desogestrel, norgestimate, gestodene, dienogest and nomegestrol share the common property of having weak or no androgenic effects, but there is great variation between agents in their pharmacokinetic properties and hormonal activities. Both desogestrel (acting as 3-keto-desogestrel) and norgestimate (acting mainly through levonorgestrel) are prodrugs. While nomegestrol is derived from 19-norprogesterone, the other compounds are 19-nortestosterone derivatives: desogestrel, norgestimate and gestodene belong to the subgroup of 13-ethyl-gonanes with an ethinyl group at C17α, and dienogest represents an estrane (13-methyl-gonane) with a cyanomethyl group at C17α

Both dienogest and nomegestrol have antiandrogenic properties. In proportion to the dose, the highest serum concentrations are observed after intake of gestodene. When combined with ethinylestradiol, gestodene and 3-keto-desogestrel accumulate in serum during daily treatment because of slowed-down elimination. This is probably caused both by binding to sex hormone-binding globulin (SHBG) and by inhibition of inactivating enzymes. Dienogest does not accumulate in serum, although at a dose of 2mg very high serum concentrations of dienogest are reached.

The most potent progestogens are gestodene and desogestrel, while the effect of dienogest and nomegestrol on endometrium and cervix is less, even though in a similar range. As the ovulation-inhibiting effect is brought about not only by receptor-mediated interactions but also by a direct inhibition of steroid biosynthesis, dienogest and nomegestrol are much less effective than gestodene, desogestrel and norgestimate. Ethinylated progestogens, particularly gestodene, have been demonstrated to inhibit cytochrome P450 enzymes. Both gestodene and desogestrel may moderately reduce SHBG levels and counteract the stimulating effect of ethinylestradiol on hepatic serum proteins, while dienogest and nomegestrol have no influence.

Compared with progestogens with androgenic properties which may restrict the stimulatory action of ethinylestradiol on haemostatic parameters, the newer progestogens do not seem to be superior with respect to haemostasis. There are no data on the direct effect of the compounds on the arterial and venous vessel wall. Due to the less pronounced antagonism on ethinylestradiol-induced changes in lipid metabolism, the newer progestogens appear to be beneficial rather than deleterious, although atherosclerosis was probably not promoted by the older formulations because of the direct effect of ethinylestradiol on the arterial wall. There is no evidence for a lesser impact of the newer progestogens on carbohydrate metabolism, which is mostly impaired by the estrogen component in oral contraceptives. Formulations containing the newer progestogens are, however, preferable in patients with hyperandrogenaemia, the symptoms of which may be improved by the suppression of total and free testosterone and an increase in SHBG; an additional beneficial effect of the antiandrogenic properties of dienogest or nomegestrol remains to be proven.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Düsterberg B, Tack JW, Krause W, et al. Pharmacokinetics and biotransformation of gestodene in man. In: Elsein M, editor. Gestodene. Carnforth: Parthenon, 1987; 35–44

    Google Scholar 

  2. Viinikka L. Metabolism of a new synthetic progestagen, Org 2969, by human liver in vitro. J Steroid Biochem 1979; 10: 353–7

    Article  PubMed  CAS  Google Scholar 

  3. Madden S, Back DJ, Martin CA, et al. Metabolism of the contraceptive steroid desogestrel by the intestinal mucosa. Br J Clin Pharmacol 1989; 27: 295–9

    Article  PubMed  CAS  Google Scholar 

  4. Back DJ, Grimmer SFM, Shenoy N, et al. Plasma concentrations of 3-keto-desogestrel after oral administration of desogestrel and intravenous administration of 3-keto-desogestrel. Contraception 1987; 35: 619–26

    Article  PubMed  CAS  Google Scholar 

  5. Viinikka L. Metabolism of a new synthetic progestagen, Org 2969, by human liver in vitro. J Steroid Biochem 1979; 10: 353–7

    Article  PubMed  CAS  Google Scholar 

  6. Madden S, Back DJ, Orme MLE. Metabolism of the contraceptive steroid desogestrel by human liver in vitro. J Steroid Biochem 1990; 35: 281–8

    Article  PubMed  CAS  Google Scholar 

  7. Madden S, Back DJ. Metabolism of norgestimate by human gastrointestinal mucosa and liver microsomes in vitro. J Steroid Biochem Mol Biol 1991; 38: 497–503

    Article  PubMed  CAS  Google Scholar 

  8. Alton KB, Hetyei NS, Shaw C, et al. Biotransformation of norgestimate in women. Contraception 1984; 29: 19–29

    Article  PubMed  CAS  Google Scholar 

  9. Hobe G, Schön R, Schade W, et al. Zur Biotransformation von Dienogest beim Menschen. In: Teichmann AT, editor. Dienog-est — Präklinik und Klinik eines neuen Gestagens. Berlin: Walter de Gruyter Verlag, 1995: 105–17

    Google Scholar 

  10. Oettel M, Kaufmann G, Kurischko A. Das endokrinologische Profil von Metaboliten des Gestagens Dienogest. Pharmazie 1993: 48: 541–5

    PubMed  CAS  Google Scholar 

  11. Cooper JM, Kellie AE. The metabolism of megestrol acetate (17α-acetoxy-6-methylpregna-4,6-diene-3,20-dione) in women. Steroids 1968; 11: 133–49

    Article  PubMed  CAS  Google Scholar 

  12. Kühl H, Jung-Hoffmann C, Heidt F. Alteration in the serum levels of gestodene and SHBG during 12 cycles of treatment with 30 μg ethinylestradiol and 75 μg gestodene. Contraception 1988; 38: 477–86

    Article  PubMed  Google Scholar 

  13. Höbe G, Klinger G, Reddersen G, et al. Radioimmunologische Bestimmung des Progestagens Dienogest im Plasma und Speichel. Pharmazie 1986; 41: 772–4

    PubMed  Google Scholar 

  14. Steingold KA, Cefalu W, Pardridge W, et al. Enhanced hepatic extraction of estrogens used for replacement therapy. J Clin Endocrinol Metab 1986; 62: 761–6

    Article  PubMed  CAS  Google Scholar 

  15. Hammond GL, Bocchinfuso WP, Orava M, et al. Serum distribution of two contraceptive progestins: 3-ketodesogestrel and gestodene. Contraception 1994; 50: 301–18

    Article  PubMed  CAS  Google Scholar 

  16. Kuhnz W, Gansau C, Fuhrmeister A. Pharmacokinetics of gestodene in 12 women who received a single oral dose of 0.075 mg gestodene and after a wash-out phase, the same dose during one treatment cycle. Contraception 1992; 46: 29–40

    Article  PubMed  CAS  Google Scholar 

  17. Kuhnz W, Baumann A, Staks T, et al. Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. Contraception 1993; 48: 303–22

    Article  PubMed  CAS  Google Scholar 

  18. Pollow K, Juchem M, Grill HJ, et al. Gestodene: a novel synthetic progestin — characterization of binding to receptor and serum proteins. Contraception 1989; 40: 325–41

    Article  PubMed  CAS  Google Scholar 

  19. Jung-Hoffmann C, Kühl H. Intra- and interindividual variations in contraceptive steroid levels during 12 treatment cycles: no relation to irregular bleeding. Contraception 1990; 42: 423–38

    Article  PubMed  CAS  Google Scholar 

  20. Guengerich FP. Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chem Res Toxicol 1990; 3: 363–71

    Article  PubMed  CAS  Google Scholar 

  21. Kuhl H, Jung-Hoffmann C, Storch A, et al. New aspects on the mechanism of action of contraceptive steroids — recent phar-macokinetic studies of low dose formulations. Adv Con-tracept 1991; 7 Suppl. 3: 149–63

    Google Scholar 

  22. Viinikka L. Radioimmunoassay of a new progestagen, ORG 2969, and its metabolite. J Steroid Biochem 1978; 9: 979–82

    Article  PubMed  CAS  Google Scholar 

  23. Hasenack HG, Bosch AMG, Käär K. Serum levels of 3-keto-desogestrel after oral administration of desogestrel and 3-keto-desogestrel. Contraception 1986; 33: 591–6

    Article  PubMed  CAS  Google Scholar 

  24. Kuhl H, Jung-Hoffmann C, Heidt F. Serum levels of 3-keto-desogestrel and SHBG during 12 cycles of treatment with 30 μg ethinylestradiol and 150 μg desogestrel. Contraception 1988; 38: 381–90

    Article  PubMed  CAS  Google Scholar 

  25. Kuhl H, Jung-Hoffmann C, Fitzner M. Prodrug versus drug effects of 150 μg desogestrel or 3-keto-desogestrel in combination with 30 μg ethinylestradiol on hormonal parameters: relevance of the peak serum level of 3 keto-desogestrel. Horm Res 1995; 44: 126–32

    Article  PubMed  CAS  Google Scholar 

  26. Kuhl H, Jung-Hoffmann C, Fitzner M, et al. Short- and long-term effects on lipid metabolism of oral contraceptives con-taing 30μg ethinylestradiol and 150μg desogestrel on 3-keto-desogestrel. Horm Res 1995; 44: 121–5

    Article  PubMed  CAS  Google Scholar 

  27. Jung-Hoffmann C, Fitzner M, Kuhl H. Oral contraceptives containing 20 or 30 μg ethinylestradiol and 150 μg desogestrel: pharmacokinetics and pharmacodynamic parameters. Horm Res 1991; 36: 238–46

    Article  PubMed  CAS  Google Scholar 

  28. McGuire JL, Phillips A, Hahn DW, et al. Pharmacologic and pharmacokinetic characteristics of norgestimate and its metabolites. Am J Obstet Gynecol 1990; 163: 2127–31

    PubMed  CAS  Google Scholar 

  29. Kuhnz W, Blöde H, Mahler M. Systemic availability of levo-norgestrel after single oral administration of a norgestimate-containing combination oral contraceptive to 12 young women. Contraception 1994; 49: 255–63

    Article  PubMed  CAS  Google Scholar 

  30. Rühl E, Kühl H. Mechanism-based inhibition of reductase activity in rat liver microsomes by synthetic progestogens. Acta Endocrinol 1992; 126 Suppl. 4: 113

    Google Scholar 

  31. Böcker R, Kleingeist B, Eichhorn M, et al. In vitro interaction of contraceptive steroids with human liver cytochrome P-450 enzymes. Adv Contracept 1991; 7 Suppl. 3: 140–8

    Google Scholar 

  32. Böcker R, Kleingeist B. Der Einfluss von Dienogest auf das humane Cytochrom P-450 Enzymsystem in vitro. In: Teichmann AT, editor. Dienogest — Präklinik und Klinik eines neuen Gestagens. Berlin: Walter de Gruyter Verlag, 1995: 141–7

    Google Scholar 

  33. Juchem M, Schaffrath M, Pollow K, et al. Dienogest: Bindungsstudien an verschiedenen Rezeptor- und Serumproteinen. In: Teichmann AT, editor. Dienogest — Präklinik und Klinik eines neuen Gestagens. Berlin: Walter de Gruyter Verlag, 1995: 119–33

    Google Scholar 

  34. Ezan E, Benech H, Bucourt R, et al. Enzyme immunoassay for nomegestrol acetate in human plasma. J Steroid Biochem Mol Biol 1993; 46: 507–14

    Article  PubMed  CAS  Google Scholar 

  35. Neumann F. Grundlagen der hormonalen Kontrazeption. In: Hammerstein J, editor. 25 Jahre hormonale Kontrazeptiva aus Berlin. Amsterdam: Excerpta Medica, 1986: 36–42

    Google Scholar 

  36. Elger W, Steinbeck H, Schillinger E, et al. Endocrine-phar-amcological profile of gestodene. In: Elstein M, editor. Gesto-dene — development of a new gestodene-containing low-dose oral contraceptive. Carnforth: Parthenon, 1987: 19–33

    Google Scholar 

  37. Eyong E, Elstein M. Comparison of the effects of levonorgestrel and gestodene on pituitary gonadotropins, follicular development and cervical mucus. In: Elstein M, editor. Gestodene — development of a new gestodene-containing low-dose oral contraceptive. Carnforth: Parthenon, 1987: 55–65

    Google Scholar 

  38. Haboubi NY, Eyong E, Chantier EN, et al. Comparative histology of the endometrium under treatment with levonorgestrel and gestodene. In: Elstein M, editor. Gestodene — development of a new gestodene-containing low-dose oral contraceptive. Carnforth: Parthenon, 1987: 73–9

    Google Scholar 

  39. Cullberg G, Lindstedt G, Lundberg PA, et al. Central and peripheral effects of desogestrel 15-60 μg daily for 21 days in healthy female volunteers. Acta Obstet Gynecol Scand 1982; Suppl. 111: 21–8

    Article  Google Scholar 

  40. Cullberg G. Androgenic, anabolic, estrogenic and antiestroge-nic effects of desogestrel and lynestrenol: effects on serum proteins and vaginal cytology. Contraception 1984; 30: 73–9

    Article  PubMed  CAS  Google Scholar 

  41. Cullberg G, Erikson O, Knutsson F, et al. Desogestrel, a new progestational compound. Acta Obstet Gynecol Scand 1982; Suppl. 111: 13–9

    Article  Google Scholar 

  42. Killinger J, Hahn DW, Phillips A, et al. The affinity of norgesti-mate for uterine progestogen receptors and its direct action on the uterus. Contraception 1985; 32: 311–9

    Article  PubMed  CAS  Google Scholar 

  43. Phillips A, Demarest K, Hahn DW, et al. Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins. Contraception 1990; 41: 399–409

    Article  PubMed  CAS  Google Scholar 

  44. Juchem M, Pollow K, Elger W, et al. Receptor binding of norgestimate — a new orally active synthetic progestational compound. Contraception 1993; 47: 283–94

    Article  PubMed  CAS  Google Scholar 

  45. Kuhnz W, Fritzemeier KH, Hegele-Hartung C, et al. Comparative progestational activity of norgestimate, levonorgestrel-oxime and levonorgestrel in the rat and binding of these compounds to the progesterone receptor. Contraception 1995; 51: 131–9

    Article  PubMed  CAS  Google Scholar 

  46. Phillips A. The selectivity of a new progestin. Acta Obstet Gynecol Scand 1990; Suppl. 152: 21–4

    Article  CAS  Google Scholar 

  47. Phillips A, Hahn DW, Klimek S, et al. A comparison of the potencies and activities of progestogens used in contraceptives. Contraception 1987; 36: 181–92

    Article  PubMed  CAS  Google Scholar 

  48. Hahn DW, Allen GO, McGuire JL. The pharmacological profile of norgestimate, a new orally active progestin. Contraception 1977; 16: 541–53

    Article  PubMed  CAS  Google Scholar 

  49. Kuhnz W, Beier S. Comparative progestational and androgenic activity of norgestimate and levonorgestrel in the rat. Contraception 1994; 49: 275–89

    Article  PubMed  CAS  Google Scholar 

  50. Eyong E, Buchi K, Elstein M. Effects of 180 μg and 250 μg norgestimate on pituitary ovarian function and cervical mucus. Fertil Steril 1988; 50: 756–60

    PubMed  CAS  Google Scholar 

  51. Mohsenian M, Moghissi KS, Borin K. Effects of norgestimate in combination with ethinyl estradiol on cervical mucus. Contraception 1981; 24: 173–81

    Article  PubMed  CAS  Google Scholar 

  52. Seliger E, Kaltwasser P, Schneider F, et al. Behandlung der Endometriose mit Dienogest — Einfluss auf den Rezeptorstatus im Endometrium und vergleichende Bindungsstudien. In: Teichmann AT, editor. Dienogest — Präklinik und Klinik eines neuen Gestagens. Berlin: Walter de Gruyter Verlag, 1995: 231–41

    Google Scholar 

  53. Moore C, Walter F, Klinger G, et al. Der Einfluss von Dienogest auf die Ovulation junger Frauen und auf ausgewählte en-dokrinologische Parameter. In: Teichmann AT, editor. Dienogest — Präklinik und Klinik eines neuen Gestagens. Berlin: Walter de Gruyter Verlag, 1995: 161–9

    Google Scholar 

  54. Oettel M, Elger W, Ernst M, et al. Experimentelle Endokrinpharmakologie von Dienogest. In: Teichmann AT, editor. Dienogest — Präklinik und Klinik eines neuen Gestagens. Berlin: Walter de Gruyter Verlag, 1995: 11–21

    Google Scholar 

  55. Botella J, Paris J, Lahlou B. The cellular mechanism of the antiandrogenic action of nomegestrol acetate, a new 19-nor-progestagen, on the rat prostate. Acta Endocrinol 1987; 115: 544–50

    PubMed  CAS  Google Scholar 

  56. Duc I, Botella J, Delansorne R, et al. Interaction of [3H]nome-gestrol acetate with cytosolic progesterone receptors from the rat uterus. Steroids 1991; 56: 325–8

    Article  PubMed  CAS  Google Scholar 

  57. Fraser DI, Padwick ML, Whitehead MI, et al. The effects of the addition of nomegestrol acetate to post-menopausal oestrogen therapy. Maturitas 1989; 11: 21–34

    Article  PubMed  CAS  Google Scholar 

  58. Botella J, Duc I, Delansorne R, et al. Regulation of rat uterine steroid receptors by nomegestrol acetate, a new 19-nor-pro-gesterone derivative. J Pharm Exp Ther 1989; 248: 758–61

    CAS  Google Scholar 

  59. Chretien FC, Dubois R. Effect of nomegestrol acetate on spinability, ferning and mesh dimension of midcycle cervical mucus. Contraception 1991; 43: 55–65

    Article  PubMed  CAS  Google Scholar 

  60. Paris J, Botella J, Fournau P, et al. Extinction of mineralocorti-coid effects in 19-norprogesterone derivatives: structure-activity relationships. J Pharm Exp Ther 1987; 243: 288–91

    CAS  Google Scholar 

  61. Botella J, Porthe-Nibelle J, Paris J, et al. Interaction of new 19-nor-progesterone derivatives with progestagen, mineralo-corticoid and glucocorticoid receptors. J Pharmacol 1986; 17: 699–706

    PubMed  CAS  Google Scholar 

  62. Paris J, Thevenot R, Bonnet P, et al. The pharmacological profile of TX 066 (17α-acetoxy-6-methyl-19-nor-4,6-pregna-diene-3,20-dione), a new oral progestative. Drug Res 1983; 33: 710–5

    CAS  Google Scholar 

  63. Bazin B, Thevenot R, Bursaux C, et al. Effect of nomegestrol acetate, a new 19-nor-progesterone derivative, on pituitaryovarian function in women. Br J Obstet Gynaecol 1987; 94: 1199–204

    Article  PubMed  CAS  Google Scholar 

  64. Fotherby K. Potency and pharmacokinetics of gestagens. Contraception 1990; 41: 533–50

    Article  PubMed  CAS  Google Scholar 

  65. Balogh A, Lautenschlager MT, Splinter FK, et al. Vergleichende Untersuchungen zum Einfluss von Ethinylestradiol-haltigen Kontrazeptiva mit Dienogest- oder Levonorgestrel-Kom-ponente auf die Cytochrom P-450-Funktion in vivo. In: Teichmann AT, editor. Dienogest — Präklinik und Klinik eines neuen Gestagens. Berlin: Walter de Gruyter Verlag, 1995: 149–59

    Google Scholar 

  66. Ortiz de Montellano PR. Suicide substrates for drug metabolizing enzymes: mechanisms and biological consequences. In: Gibson GG, editor. Progress in drug metabolism. London: Taylor & Francis, 1988: 99–148

    Google Scholar 

  67. Kuhl H, Jung-Hoffmann C. Pharmacokinetics of hormonal contraceptives. In: Moeloek FA, Affandi B, Trounson AO, editors. Advances in human reproduction. New York: Parthenon Publications, 1995: 133–41

    Google Scholar 

  68. Fern M, Rose DP, Fern EB. Effect of oral contraceptives on plasma androgenic steroids and their precursors. Obstet Gynecol 1978; 51: 541–4

    Article  PubMed  CAS  Google Scholar 

  69. Van der Vange N. Seven low dose oral contraceptives and their influence on metabolic pathways and ovarian activity [thesis]. Utrecht: Univ. of Utrecht, 1986: chap. 4, 71–84

    Google Scholar 

  70. Kim-Björklund T, Landgren BM, Hamberger L. Is the contraceptive effect of 300 μg norethisterone mainly peripheral or central? Contraception 1992; 45: 57–66

    Article  PubMed  Google Scholar 

  71. Schürenkämper P, Lisse K. Effects of the new progestagen STS 557 on the biosynthesis of steroids in tissue slices of the human ovary. Exp Clin Endocrinol 1985; 86: 185–9

    Article  PubMed  Google Scholar 

  72. Elger W, Steinbeck H, Schilllinger E, et al. Endocrine-pharmacological profile of gestodene. Adv Contracept Deliv Syst 1986; 2: 182–97

    CAS  Google Scholar 

  73. Phillips A, Demarest K, Hahn DW, et al. Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins. Contraception 1990; 41: 399–410

    Article  PubMed  CAS  Google Scholar 

  74. Jung-Hoffmann C, Kuhl H. Divergent effects of two low-dose oral contraceptives on sex hormone-binding globulin and free testosterone. Am J Obstet Gynecol 1987; 156: 199–203

    PubMed  CAS  Google Scholar 

  75. van der Vange N, Blankenstein MA, Kloosterboer HJ, et al. Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone. Contraception 1990; 41: 345–52

    Article  PubMed  Google Scholar 

  76. Ain KB, Mori Y, Refetoff S. Reduced clearance rate of thyrox-ine-binding globulin (TBG) with increased sialylation: a mechanism for estrogen-induced elevation of serum TBG concentration. J Clin Endocrinol Metab 1987; 65: 689–96

    Article  PubMed  CAS  Google Scholar 

  77. Kauppinen-Mäkelin R, Kuusi T, Ylikorkala O et al. Contraceptives containing desogestrel or levonorgestrel have different effects on serum lipoproteins and post-heparin plasma lipase activities. Clin Endocrinol 1992; 36: 203–9

    Article  Google Scholar 

  78. Jung-Hoffmann C, Heidt F, Kuhl H. Effect of two oral contraceptives containing 30 μg ethinylestradiol and 75 μg gestodene or 150 μg desogestrel upon various hormonal parameters. Contraception 1988; 38: 593–603

    Article  PubMed  CAS  Google Scholar 

  79. Wiegratz I, Jung-Hoffmann C, Kuhl H. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins. Contraception 1995; 51: 341–6

    Article  PubMed  CAS  Google Scholar 

  80. Moore C, Walter F, Klinger G et al. Der Einfluss von Dienogest auf die Ovulation junger Frauen und auf ausgewählte endo-krinologische Parameter. In: Teichmann AT, editor. Dienogest — Präklinik und Klinik eines neuen Gestagens. Berlin: Walter de Gruyter Verlag, 1995: 161–9

    Google Scholar 

  81. Basdevant A, Pelissier C, Conard J, et al. Effects of nomegestrol acetate (5 mg/d) on hormonal, metabolic and hemostatic parameters in premenopausal women. Contraception 1991; 44: 599–605

    Article  PubMed  CAS  Google Scholar 

  82. Kuhl H. Pharmacokinetics of oestrogens and progestogens. Maturitas 1990; 12: 171–97

    Article  PubMed  CAS  Google Scholar 

  83. Prasad RNV, Koh S, Ratnam SS. Effects of three types of combined O.C. pills on blood coagulation, fibrinolysis and platelet function. Contraception 1989; 39: 369–83

    Article  PubMed  CAS  Google Scholar 

  84. Cohen H, Mackie IJ, Walshe K, et al. A comparison of the effects of two triphasic oral contraceptives on haemostasis. Br J Haematol 1988; 69: 259–63

    Article  PubMed  CAS  Google Scholar 

  85. Omsjo IH, Oian P, Maltau JM, et al. Effects of two triphasic oral contraceptives containing ethinylestradiol plus levonorgestrel or gestodene on blood coagulation and fibrinolysis. Acta Ob-stet Gynecol Scand 1989; 68: 27–30

    Article  CAS  Google Scholar 

  86. Refn H, Kjaer A, Lebech AM, et al. Metabolic changes during tratment with two different progestogens. Am J Obstet Gynecol 1990; 163: 374–7

    PubMed  CAS  Google Scholar 

  87. Ball MJ, Ashwell E, Jackson M, et al. Comparison of two triphasic contraceptives with different progestogens: effects on metabolism and coagulation proteins. Contraception 1990; 41: 363–76

    Article  PubMed  CAS  Google Scholar 

  88. Bonnar J. Coagulation effects of oral contraception. Am J Obstet Gynecol 1987; 157: 1042–8

    PubMed  CAS  Google Scholar 

  89. Hillard TC, Bourne TH, Whitehead MI, et al. Differential effects of transdermal estradiol and sequential progestogens on impedance to flow within the uterine arteries of post-menopausal women. Fertil Steril 1992; 58: 959–63

    PubMed  CAS  Google Scholar 

  90. Sarrel P. Effects of ovarian steroids on the cardiovascular system. In: Ginsberg J, editor. The circulation in the female. Car-nforth: Parthenon, 1989: 117–41

    Google Scholar 

  91. Goodrich SM, Wood JE. Peripheral venous distensibility and velocity of venous blood flow during pregnancy or during oral contraceptive therapy. Am J Obstet Gynecol 1964; 90: 740–4

    PubMed  CAS  Google Scholar 

  92. Fawer R, Dettling A, Weihs D, et al. Effect of the menstrual cycle, oral contraception and pregnancy on forearm blood flow, venous distensibility and clotting factors. Eur J Clin Pharmacol 1978; 13: 251–7

    Article  PubMed  CAS  Google Scholar 

  93. Bonnar J. Changes in coagulation and fibrinolysis with low dose oral contraceptives. Adv Contracept 1991; 7 Suppl. 3: 285–91

    Google Scholar 

  94. Thomson JM, Poller L, Bocaz JA, et al. A multicentre study of coagulation and haemostatic variables during oral contraception: variations with four formulations. Br J Obstet Gynaecol 1991; 98: 1117–28

    Article  Google Scholar 

  95. Winkler UH, Koslowski S, Oberhoff C, et al. Changes of the dynamic equilibrium of hemostasis associated with the use of low-dose oral contraceptives: a controlled study of cyproter-one acetate containing oral contraceptives combined with either 35 or 50 μg ethinyl estradiol. Adv Contracept 1991; 7 Suppl. 3: 273–84

    Google Scholar 

  96. Winkler UH, Bühler K, Oberhoff C, et al. The dynamic balance of hemostasis: a key for understanding thromboembolism in oral contraceptive users. In: Genazzani AR, Petraglia F, Boselli F, et al., editors. Current research in gynecology and obstetrics. Carnforth: Parthenon, 1991: 389–94

    Google Scholar 

  97. Briel RC, Schindler AE, Zwirner M et al. Veränderungen gerinnungsphysiologischer Parameter durch orale Kontrazeption mit einem Desogestrel-haltigen Zweiphasenpräparat bei Rauchern und Nichtrauchern. Hamostaseologie 1988; 8/3: 1–11

    Google Scholar 

  98. Melis GB, Fruzzetti F, Nicoletti I et al. A comparative study on the effects of a monophasic pill containing desogestrel plus 20 μg ethinylestradiol, a triphasic combination containing levonorgestrel and a monophasic combination containing gestodene on coagulatory factors. Contraception 1991; 43: 23–31

    Article  PubMed  CAS  Google Scholar 

  99. Inauen W, Baumgartner HR, Haeberli A, et al. Excessive deposition of fibrin, platelets and platelet thrombi on vascular sub-endothelium during contraceptive drug treatment. Thromb Haemostas 1987; 57: 306–9

    CAS  Google Scholar 

  100. Gram J, Munkvad S, Jespersen J. Enhanced generation and resolution of fibrin in women above the age of 30 years using oral contraceptives low in estrogen. Am J Obstet Gynecol 1990; 163: 438–42

    PubMed  CAS  Google Scholar 

  101. Petersen K, Sidelmann J, Skouby O, et al. Effects of monphasic low-dose oral contraceptives on fibrin formation and resolution in young women. Am J Obstet Gynecol 1993; 168: 32–8

    PubMed  CAS  Google Scholar 

  102. Kuusi T, Nikkilä EA, Tikkanen MJ, et al. Effects of two pro-gestins with different androgenic properties on hepatic endo-thelial lipase and high density lipoprotein2. Atherosclerosis 1985; 54: 251–62

    Article  PubMed  CAS  Google Scholar 

  103. Tikkanen MJ, Kuusi T, Nikkilä EA, et al. Post-menopausal hormone replacement therapy: effects of progestogens on serum lipids and lipoproteins: a review. Maturitas 1986; 8: 7–17

    Article  PubMed  CAS  Google Scholar 

  104. Kuhl H, März W, Jung-Hoffmann C, et al. Time-dependent alterations in lipid metabolism during treatment with low-dose oral contraceptives. Am J Obstet Gynecol 1990; 163: 363–9

    PubMed  CAS  Google Scholar 

  105. Speroff L, DeCherney A. Evaluation of a new generation of oral contraceptives. Obstet Gynecol 1993; 81: 1034–47

    PubMed  CAS  Google Scholar 

  106. Janaud AJ, Rouffy J, Upmalis D, et al. A comparison study of lipid and androgen metabolism with a triphasic oral contraceptive formulation containing norgestimate or levonorgestrel. Acta Obstet Gynecol Scand 1992; 71: 33–8

    Article  Google Scholar 

  107. Silfverstolpe G, Johnson P, Samsioe G, et al. Lipid metabolic studies in oophorectomized women: effects induced by the addition of norethisterone acetate to two different oestrogens on serum individual phospholipids and serum lecithin fatty acid composition. Acta Endocrinol 1981; 96: 527–33

    PubMed  CAS  Google Scholar 

  108. Kuhl H, März W, Jung-Hoffmann C, et al. Effect on lipid metabolism of a biphasic desogestrel-containing oral contraceptive: divergent changes in apolipoprotein B and E and transitory decrease in Lp(a) levels. Contraception 1993; 47: 69–83

    Article  PubMed  CAS  Google Scholar 

  109. Spellacy WN. Carbohydrate metabolism during treatment with estrogen, progestogen and low-dose oral contraceptives. Am J Obstet Gynecol 1982; 142: 732–4

    PubMed  CAS  Google Scholar 

  110. van den Ende A, Liitlens A, van Wayjen RGA, et al. Effects of the oral contraceptive combination 0.150 mg desogestrel plus 0.020 mg ethinylestradiol on carbohydrate metabolism in healthy female volunteers. Acta Obstet Gynecol Scand 1987; Suppl. 144: 29–32

    Article  Google Scholar 

  111. Godsland IF, Crook D, Simpson R, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990: 323: 1375–81

    Article  PubMed  CAS  Google Scholar 

  112. Kuhl H, Jung-Hoffmann C, Weber J, et al. The effect of a biphasic desogestrel-containing oral contraceptive on carbohydrate metabolism and various hormonal parameters. Contraception 1993; 47: 55–68

    Article  PubMed  CAS  Google Scholar 

  113. Miccoli R, Orlandi MC, Fruzzetti O, et al. Metabolic effects of three new low-dose pills: a six-month experience. Contraception 1989; 39: 643–52

    Article  PubMed  CAS  Google Scholar 

  114. Spellacy WN, Tsibris JCM, Hunter-Bonner DL, et al. Six month carbohydrate metabolism studies in women using oral contraceptives containing gestodene and ethinylestradiol. Contraception 1992; 45: 533–9

    Article  PubMed  CAS  Google Scholar 

  115. Spellacy WN, Tsibris AMN, Tsibris JCM, et al. Carbohydrate metabolism studies after one year of using an oral contraceptive containing gestodene and ethinyl estradiol. Contraception 1994; 49: 125–30

    Article  PubMed  CAS  Google Scholar 

  116. Godsland IF, Walton C, Felton C, et al. Insulin resistance, secretion, and metabolism in users of oral contraceptives. J Clin Endocrinol Metab 1991; 74: 64–70

    Article  Google Scholar 

  117. Crook D, Gosland I, Worthington M, et al. A comparative metabolic study of two low-dose oral contraceptives containing gestodene and desogestrel progestins. Am J Obstet Gynecol 1993; 169: 1183–9

    PubMed  CAS  Google Scholar 

  118. Godsland IF, Crook D. Update on the metabolic effects of ste-roidal contraceptives and their relationship to cardiovascular disease risk. Am J Obstet Gynecol 1994; 170: 1528–36

    PubMed  CAS  Google Scholar 

  119. van der Vange N, Kloosterboer HJ, Haspels AA. Effect of seven low-dose combined oral contraceptive preparations on carbohydrate metabolism. Am J Obstet Gynecol 1987; 156: 918–22

    PubMed  Google Scholar 

  120. Dorangeon P, Thomas JL, Choisy H, et al. Effects of nomegestrol acetate on carbohydrate metabolism. Diabete Metab 1993; 19: 441–5

    PubMed  CAS  Google Scholar 

  121. Tsibris JCM, Hunt LT, Ballejo G, et al. Selective inhibition of protein disulfide isomerase by estrogens. J Biol Chem 1989; 264: 13967–70

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynaecology, Division of Gynaecological Endocrinology, J.W. Goethe University, Theodor-Stern-Kai 7, D-60590, Frankfurt am Main, Germany

    Herbert Kuhl

Authors
  1. Herbert Kuhl
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kuhl, H. Comparative Pharmacology of Newer Progestogens. Drugs 51, 188–215 (1996). https://doi.org/10.2165/00003495-199651020-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199651020-00002

Keywords

Search

Navigation